Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.
Rhea-AI Summary
Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.
A live webcast will be available under the company’s Investor "Events & Presentations" page and the presentation will be available for replay following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KPTI
On Dec 1, the day this news came out, KPTI closed 2.31% above the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Conference time
- 10:30 a.m. ET
- Piper Sandler 37th Annual Healthcare Conference fireside chat on Dec 4, 2025
Historical Context
-
Announcement of Baird virtual fireside chat with external expert.
-
Stock options and RSUs granted to seven new employees.
-
Piper Sandler fireside chat with webcast and replay access.
-
RSU award to a new hire under inducement plan.
-
Q3 2025 results, guidance reaffirmation and trial enrollment update.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-piper-sandler-37th-annual-healthcare-conference-302624649.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
